Screener
Nuvectis Pharma, Inc. NVCT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(6,050) | $(5,332) |
| Adjustments to reconcile loss to net cash used in operating activities: Cost of share-based payments | 1,850 | 1,368 |
| Changes in operating assets and liabilities: | ||
| Increase in other current assets | (193) | (210) |
| (Decrease)/increase in accounts payable | (1,579) | 494 |
| (Decrease)/increase in accrued liabilities | (79) | 25 |
| Decrease in employee compensation and benefits | (460) | (519) |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s stock-based comp?
- Nuvectis Pharma, Inc. (NVCT) reported stock-based comp of $1.85M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s stock-based comp changed year-over-year?
- Nuvectis Pharma, Inc.'s stock-based comp increased by 35.2% year-over-year, from $1.37M to $1.85M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s stock-based comp?
- Over 3 years (2022 to 2025), Nuvectis Pharma, Inc.'s stock-based comp has grown at a 52.3% compound annual growth rate (CAGR), from $1.71M to $6.03M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Nuvectis Pharma, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude